Table. 3.

Table. 3.

Treatment and prognostic variables of Ewing’s sarcoma family tumors cohort

Variable Total (n=12) Patients with event (n=6) Patients without event (n=6) P-value
Metastatic disease 6 (50.0%) 6 (100.0%) 0 0.0022
Lung mets 5 (42.0%) 5 (83.0%)
Chemotherapy 12 (100.0%) 6 (100.0%) 6 (100.0%) 1.0000
Limb salvage surgery 8 (66.7%) 4 (66.6%) 4 (66.6%) 0.4545
Negative microscopic margins 5 (42.0%) 3 (50.0%) 2 (33.3%) 0.6104
Tumor necrosis >90% 7 (58.3%) 4 (66.6%) 3 (50.0%) 1.0000
Radiotherapy 12 (100.0%) 6 (100.0%) 6 (100.0%)
Functional disability at follow-up 2 (16.7%) 1 (16.7%) 1 (16.7%) 1.0000
Death 4 (25.0%) 4 (66.6%) 0 0.0606
Disease progression as cause of death 4 (25.0%) 4 (66.6%) 0 0.066
Clin Pediatr Hematol Oncol 2024;31:29-35
© 2024 Clin Pediatr Hematol Oncol